Ligand Pharmaceuticals Incorporated (LGND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.18B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ligand Pharmaceuticals Incorporated (LGND) Financials: Revenue, Profit and Cash Flow
Ligand Pharmaceuticals reported revenue of $268.09M for the fiscal year ended Dec 31, 2025, up 60.4% from the year before. That year, net income was $124.45M with a net margin of 46.4%, operating cash flow was $49.36M and free cash flow was $48.91M. The quarter ended Sep 30, 2026 had revenue of $78.75M and net income of -$28.48M.
Revenue and Margins
The operating margin was 15.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $108.97M, a compound annual rate of 10.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $268.09M | +60.4% | 94.6% | 15.3% | 46.4% |
| Dec 2024 | $167.13M | +27.3% | 93.4% | -13.5% | -2.4% |
| Dec 2023 | $131.31M | -33.1% | 92.0% | 9.1% | 39.7% |
| Dec 2022 | $196.25M | -18.8% | 73.1% | 1.5% | -17.0% |
| Dec 2021 | $241.54M | +47.7% | 74.3% | 43.0% | 23.7% |
| Dec 2020 | $163.56M | +36.0% | 81.4% | 22.9% | -1.8% |
| Dec 2019 | $120.28M | -52.2% | 100.0% | 671.0% | 523.2% |
| Dec 2018 | $251.45M | +78.2% | 97.5% | 65.1% | 57.0% |
| Dec 2017 | $141.10M | +29.5% | 100.0% | 48.2% | 8.9% |
| Dec 2016 | $108.97M | N/A | 94.9% | 40.3% | -1.5% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $268.09M | $167.13M | $131.31M | $196.25M | $241.54M | $163.56M | $120.28M | $251.45M | $141.10M | $108.97M |
| Cost of revenue | $14.55M | $11.07M | $10.51M | $52.83M | $62.18M | $30.42M | $0 | $6.34M | $0 | $5.57M |
| Gross profit | $253.54M | $156.06M | $120.80M | $143.42M | $179.37M | $133.14M | $120.28M | $245.12M | $141.10M | $103.40M |
| Research and development | $81.18M | $21.43M | $24.54M | $36.08M | $32.10M | $40.50M | $55.91M | $27.86M | $26.89M | $21.22M |
| Operating income | $41.00M | -$22.61M | $11.94M | $3.04M | $103.85M | $37.50M | $807.08M | $163.73M | $68.08M | $43.88M |
| Net income | $124.45M | -$4.03M | $52.15M | -$33.36M | $57.14M | -$2.98M | $629.30M | $143.32M | $12.56M | -$1.64M |
| EBITDA | $163.62M | N/A | $49.54M | $65.03M | $168.79M | $91.69M | $866.35M | $238.30M | $93.17M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78.75M | $63.69M | $51.72M | $59.67M | $115.46M | $47.63M | $45.33M | $42.81M | $51.81M | $41.53M | $30.98M | $28.10M |
| Gross profit | $76.10M | $60.48M | $48.45M | $56.67M | $111.66M | $44.72M | $40.48M | $39.98M | $49.36M | $38.63M | $28.10M | $19.26M |
| Operating income | -$15.76M | $8.59M | $17.37M | $13.84M | $55.39M | $8.44M | -$36.22M | -$9.64M | $3.14M | -$19.10M | $2.99M | -$3.36M |
| Net income | -$28.48M | $48.51M | -$13.35M | $44.78M | $117.27M | $4.85M | -$42.45M | -$31.09M | -$7.17M | -$51.91M | $86.14M | $18.19M |
Balance Sheet
As of Dec 2025, total debt of $446.19M exceeded cash and equivalents by $271.26M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.56B | $941.77M | $787.22M | $762.67M | $1.30B | $1.36B | $1.49B | $1.26B | $671.02M | $601.59M |
| Current assets | $832.27M | $331.56M | $237.43M | $263.60M | $464.75M | $500.56M | $1.12B | $870.54M | $237.02M | $163.05M |
| Cash and equivalents | $174.93M | $72.31M | $22.95M | $45.01M | $19.52M | $47.62M | $71.54M | $117.16M | $20.62M | $18.75M |
| Total liabilities | $543.42M | $111.33M | $86.30M | $165.18M | $476.43M | $652.76M | $727.68M | $699.89M | $252.37M | $230.73M |
| Short-term debt | $0 | $1.29M | $410.00K | $76.69M | $0 | $8.48M | $1.25M | $26.43M | $224.53M | $212.91M |
| Long-term debt | $446.19M | $0 | N/A | N/A | $320.72M | $442.29M | $638.96M | $609.86M | $0 | $29.56M |
| Shareholder equity | $1.02B | $830.44M | $700.91M | $597.49M | $821.16M | $709.52M | $767.23M | $560.91M | $399.79M | $341.29M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.24B | $2.19B | $1.53B | $1.56B | $1.48B | $948.60M | $905.43M | $941.77M | $954.87M | $866.40M | $913.87M | $787.22M |
| Total liabilities | $1.28B | $1.22B | $534.78M | $543.42M | $526.60M | $120.08M | $109.90M | $111.33M | $113.69M | $91.21M | $107.35M | $86.30M |
| Cash and equivalents | $55.96M | $1.01B | $115.08M | $174.93M | $139.38M | $67.67M | $47.99M | $72.31M | $63.62M | $18.14M | $50.09M | $22.95M |
| Shareholder equity | $961.76M | $967.52M | $997.32M | $1.02B | $950.17M | $828.53M | $795.53M | $830.44M | $841.18M | $775.20M | $806.52M | $700.91M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.1% of operating cash flow. Share repurchases came to 30.7% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $49.36M | $97.05M | $49.58M | $137.85M | $78.80M | $54.59M | -$29.34M | $194.06M | $88.57M | $60.73M |
| Capital expenditures | $452.00K | $76.82M | $3.52M | $17.92M | $8.76M | $4.46M | $2.55M | $887.00K | $2.16M | $1.85M |
| Free cash flow | $48.91M | $20.23M | $46.06M | $119.93M | $70.04M | $50.13M | -$31.89M | $193.17M | $86.41M | $58.88M |
| Dividends paid | N/A | N/A | N/A | $6.80M | $0 | $0 | $3.00M | N/A | $0 | $0 |
| Share repurchases | $15.00M | $0 | $0 | N/A | $18.45M | $78.00M | $453.43M | $152.96M | $1.97M | $3.90M |
| Investing cash flow | -$377.32M | -$143.66M | -$11.68M | $163.62M | $30.52M | $231.65M | $466.92M | -$423.27M | -$79.18M | -$134.41M |
| Financing cash flow | $428.22M | $97.14M | -$59.95M | -$275.99M | -$137.76M | -$310.55M | -$485.17M | $328.58M | -$7.52M | -$4.99M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.59M | $24.02M | $48.69M | $45.91M | $13.09M | $15.80M | -$25.45M | $28.47M | $36.53M | $13.31M | $18.73M | $8.06M |
| Capital expenditures | $142.00K | $26.00K | $228.00K | $9.00K | $15.00K | $214.00K | $214.00K | $712.00K | $596.00K | $75.41M | $105.00K | $417.00K |
| Free cash flow | -$27.73M | $23.99M | $48.46M | $45.91M | $13.07M | $15.59M | -$25.66M | $27.76M | $35.93M | -$62.09M | $18.63M | $7.65M |
Frequently Asked Questions About LGND
What is Ligand Pharmaceuticals' annual revenue?
Ligand Pharmaceuticals reported revenue of $268.09M for the fiscal year ended Dec 31, 2025.
How fast is Ligand Pharmaceuticals' revenue growing?
Revenue was up 60.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 11.0%.
Is Ligand Pharmaceuticals profitable?
Yes. Ligand Pharmaceuticals reported net income of $124.45M for the fiscal year ended Dec 31, 2025, with a net margin of 46.4%.
How much free cash flow does LGND generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $49.36M minus capital expenditures of $452.00K produced free cash flow of $48.91M.
How much debt does Ligand Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $446.19M, short-term debt of $0 and cash and equivalents of $174.93M.
LGND pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors